Sri Lanka Pharmaceuticals & Healthcare Report

Published 13 March 2015

  • 83 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Sri Lanka Pharmaceuticals & Healthcare Report

Table of Contents

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Business Environment
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sri Lanka 2010-2018)
15
Healthcare Market Forecast
16
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2010-2018)
17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2010-2018)
17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sri Lanka 2010-2018)
18
Prescription Drug Market Forecast
19
Pharmaceutical Trade Forecast
20
Table: Pharmaceutical Trade Data And Forecasts (Sri Lanka 2012-2018)
21
Table: Pharmaceutical Trade Data And Forecasts local currency (Sri Lanka 2012-2018)
22
Other Healthcare Data
23
Key Risks To BMI's Forecast Scenario
25
Macroeconomic Forecasts
26
Economic Analysis
26
Rising Food And Garment Exports Driving Manufacturing
26
Public Infrastructure Development Supportive Of Growth
27
Services Sector Poised For Strong Growth
28
Table: Economic Activity (Sri Lanka 2009-2018)
29
Industry Risk Reward Ratings
30
Asia Pacific Risk/Reward Ratings
30
Sri Lanka Risk/Reward Ratings
36
Rewards
36
Risks
36
Market Overview
37
Industry Trends And Developments
38
Epidemiology
38
Healthcare Sector
42
Hospital Infrastructure
43
Healthcare Financing
46
Clinical Trials
46
Regulatory Development
47
Regulatory Regime
47
Regulatory Developments
49
Counterfeits
51
Pricing And Reimbursement Regimes
53
Pricing And Reimbursement Developments
54
Supply Chain
55
Competitive Landscape
57
Pharmaceutical Industry
57
Table: Local Drug Manufacturers
58
Pharmaceutical Industry Developments
59
Pharmaceutical Distribution And Retail
60
Company Profile
61
State Pharmaceuticals Corporation (SPC)
61
Hemas Holdings
65
GlaxoSmithKline
68
Demographic Forecast
71
Table: Sri Lanka's Population By Age Group, 1990-2020 ('000)
72
Table: Sri Lanka's Population By Age Group, 1990-2020 (% of total)
73
Table: Sri Lanka's Key Population Ratios, 1990-2020
74
Table: Sri Lanka's Rural And Urban Population, 1990-2020
74
Glossary
75
Methodology
77
Pharmaceutical Expenditure Forecast Model
77
Healthcare Expenditure Forecast Model
77
Notes On Methodology
78
Risk/Reward Ratings Methodology
79
Ratings Overview
80
Table: Pharmaceutical Risk/Reward Ratings Indicators
80
Indicator Weightings
81

The Sri Lanka Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sri Lanka Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sri Lanka pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Sri Lanka, to test other views - a key input for successful budgeting and strategic business planning in the Sri Lankan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Sri Lankan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Sri Lanka.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc